News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Death of a Drug Class Shows Difficulty of Using Gene Data to Design Drugs



7/10/2013 8:15:42 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

This morning, Roche announced that it was stopping all clinical trials of an experimental diabetes drug called aleglitazar because it was not preventing heart attacks and strokes as the company expected, but was causing side effects that reportedly included heart failure, kidney problems, and an increase in fractures.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES